Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
暂无分享,去创建一个
A. Iwase | N. Fuse | S. Matsumoto | K. Yoshikawa | S. Mizoue | T. Nakano
[1] C. Owsley,et al. Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence Among African Americans: “Glaucoma Management Optimism for African Americans Living with Glaucoma” (GOAL) , 2016, Current eye research.
[2] Tianjing Li,et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. , 2016, Ophthalmology.
[3] A. Iwase,et al. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study , 2015, Advances in Therapy.
[4] I. Floriani,et al. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure , 2015, Clinical ophthalmology.
[5] H. Sasaki,et al. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[6] T. S. Wu,et al. Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension , 2014, The Annals of pharmacotherapy.
[7] F. Topouzis,et al. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice , 2014, Expert opinion on pharmacotherapy.
[8] I. Floriani,et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension , 2013, British Journal of Ophthalmology.
[9] I. Floriani,et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[10] H. Moreira,et al. Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy , 2012, Clinical ophthalmology.
[11] S. S. Abeysinghe,et al. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database , 2011, British Journal of Ophthalmology.
[12] M. Della Paolera,et al. Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[13] J. A. Stewart,et al. Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy , 2010, Clinical ophthalmology.
[14] E. Higginbotham. Considerations in glaucoma therapy: fixed combinations versus their component medications , 2009, Clinical ophthalmology.
[15] J. D. Cascajosa,et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. , 2009 .
[16] T. Raber,et al. Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[17] H. Maier,et al. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol , 2007, Advances in therapy.
[18] B. Svarstad,et al. Patient-reported behavior and problems in using glaucoma medications. , 2006, Ophthalmology.
[19] A. Iwase,et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. , 2005, Ophthalmology.
[20] A. Iwase,et al. The prevalence of primary open-angle glaucoma in Japanese*1The Tajimi Study , 2004 .
[21] A. Iwase,et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. , 2004, Ophthalmology.
[22] E. E. Hartmann,et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.
[23] Douglas R. Anderson,et al. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.
[24] S. Drance,et al. Progression of glaucomatous field defects despite successful filtration. , 1977, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[25] J. Robinson,et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. , 1974, Journal of pharmaceutical sciences.